E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Giant Cell Tumor (GCT) of bone |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10005968 |
E.1.2 | Term | Bone giant cell tumor |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Primary Objectives: To evaluate response to treatment of denosumab in subjects with recurrent or unresectable GCT. Response is defined as: • elimination of giant cells, or doubling of the percentage of apoptotic giant cells, relative to baseline; or, • lack of progression of the largest lesion at week 25 by radiographic measurements
|
|
E.2.2 | Secondary objectives of the trial |
Secondary Objectives: • To measure serum trough levels of denosumab • To evaluate the degree of suppression of bone turnover • To evaluate the safety profile of denosumab • To evaluate the incidence of serum anti- denosumab antibody formation |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
4.1.1 Adult subjects (≥18 years of age) with histologically confirmed giant cell tumor who have measurable (defined as being at least 10 millimeters [mm] in size in the greatest dimension) recurrent GCT confirmed by radiology or unresectable GCT 4.1.2 ECOG performance status of 0, 1, or 2 4.1.3 Before any study- specific procedure is performed, the appropriate written informed consent must be obtained. |
|
E.4 | Principal exclusion criteria |
4.2.1 Subjects for whom palliative resection is planned: planned surgical intervention of the affected limb/area 28 days or less after administration of the first dose of denosumab 4.2.2 Radiation to affected region within 28 days before enrollment to study 4.2.3 Known diagnosis of osteosarcoma or brown tumor of bone [osteitis fibrosa cystica]) 4.2.4 Known history of second malignancy within the past 5 years, except for basal cell carcinoma or cervical carcinoma in situ 4.2.5 Prior treatment with denosumab 4.2.6 Concurrent treatment with IV or oral bisphosphonates, calcitonin or interferon alpha- 2a 4.2.7 Females of child- bearing potential who are not willing to use adequate contraceptive methods while on study and for 12 months post study, are pregnant (eg, positive urine or serum HCG test), or breast feeding 4.2.8 Men who are not willing to use adequate contraceptive methods while on study and for 12 months post- study 4.2.9 Thirty days or less since receiving an investigational product or device in another clinical study. Current enrollment in another clinical study is not permitted unless the purpose of the study is for long- term follow- up/survival data 4.2.10 Known sensitivity to any of the products to be administered during dosing |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Response rate among evaluable subjects: Response is defined as: For subjects who have tissue samples obtained and measured by histopathology: • elimination of giant cells, or; • doubling of the percentage of apoptotic giant cells relative to baseline, based on the following: - If the baseline ( pre- dose) percentage of apoptotic cells falls between 0 and 25%, then the post- dose percentage of apoptotic cells must be 50% or greater, or; - If the baseline ( pre- dose) percentage of apoptotic cells falls between 26% and 50%, then the post-dose percentage of apoptotic cells must be double relative to the baseline percentage ( ie, between 52% and 100%, respectively), or; - If the baseline ( pre- dose) percentage of apoptotic cells is greater than 50%, then 100% elimination of giant cells must occur.
For subjects with both a core biopsy and resected tissue obtained, the sample closest to week 25 will be used in the analysis. For subjects who only have radiographs obtained and no tissue samples: Lack of progression of the largest lesion, defined as no change in the volumetric measurement of the lesion by week 25, compared with baseline. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.5.1 | Number of sites anticipated in the EEA | 1 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 24 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 24 |
E.8.9.2 | In all countries concerned by the trial days | 0 |